Evidence for the use of vilazodone in the treatment of major depressive disorder

Bibliography

• Gelenberg AJ, Freeman MP, Markowitz JC, Practice guideline for the treatment of patients with major depressive disorder. 3rd edition. American Psychiatric Association 2010
   Google Scholar
• Rizvi SJ, Kennedy SH. Emerging drugs for major depressive disorder: an update. Expert Opin Emerg Drugs 2012;17(3):285-94
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Highlights of the international consensus statement on major depressive disorder. J Clin Psychiatry 2011;72(6):e21
   PubMedGoogle Scholar
• Schulberg HC, Katon W, Simon GE, Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55(12):1121-7
   PubMed Web of Science ®Google Scholar
• Reed CR, Kajdasz DK, Whalen H, The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin 2012;28(1):27-39
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379(9820):1045-55
   PubMed Web of Science ®Google Scholar
• Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006;60(4):482-91
   PubMed Web of Science ®Google Scholar
• Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;403:17-25
   PubMedGoogle Scholar
• Sarko J. Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am 2000;18(4):637-54
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Saracino MA, Selective Serotonin Reuptake Inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012;19(12):1846-63
   PubMed Web of Science ®Google Scholar
• Strohmaier J, Wust S, Uher R, Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2011;12(7):528-38
   PubMed Web of Science ®Google Scholar
• Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006;114(6):384-97
   PubMed Web of Science ®Google Scholar
• Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Aust NZ J Psychiatry 2009;43(9):795-808
   PubMed Web of Science ®Google Scholar
• Breen R, McCormac RJ. A fresh look at management of depression. How to choose and use the newer antidepressant drugs. Postgrad Med 2002;112(3):28-30; 33-4, 37-40
   PubMed Web of Science ®Google Scholar
• Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: study outcomes. J Psychosoc Nurs Ment Health Serv 2008;46(10):21-4
   Web of Science ®Google Scholar
• Gibbons RD, Hur K, Brown CH, Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; Epub ahead of print
   Google Scholar
• Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012;37(4):851-64
   PubMed Web of Science ®Google Scholar
• Leucht S, Hierl S, Kissling W, Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012;200(2):97-106
   PubMed Web of Science ®Google Scholar
• Bech P. Is the antidepressive effect of second-generation antidepressants a myth? Psychol Med 2010;40(2):181-6
   PubMedGoogle Scholar
• Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009;18(11):1753-64
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amargos-Bosch M, The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29(4):252-65
   PubMed Web of Science ®Google Scholar
• Olver JS, Cryan JF, Burrows GD, Pindolol augmentation of antidepressants: a review and rationale. Aust NZ J Psychiatry 2000;34(1):71-9
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Starr KR, Langmead CJ, Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510(1-2):49-57
   PubMed Web of Science ®Google Scholar
• Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7(2):139-47
   PubMedGoogle Scholar
• Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs 2011;25(7):615-27
   PubMed Web of Science ®Google Scholar
• Laughren TP, Gobburu J, Temple RJ, Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72(9):1166-73
   PubMed Web of Science ®Google Scholar
• Owen RT. Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc) 2011;47(7):531-7
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug Approval Package. Viibryd (vilazodone hydrochloride) Tablets. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000TOC.cfm [Accessed 26 April 2012]
   Google Scholar
• Viibryd (vilazodone) [prescribing information]. © 2012 Forest Laboratories, Inc; NY
   Google Scholar
• de Paulis T. Drug evaluation: vilazodone–a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 2007;10(3):193-201
   PubMed Web of Science ®Google Scholar
• Rickels K, Athanasiou M, Robinson DS, Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(3):326-33
   PubMed Web of Science ®Google Scholar
• Khan A, Cutler AJ, Kajdasz DK, A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72(4):441-7
   PubMed Web of Science ®Google Scholar
• Robinson DS, Kajdasz DK, Gallipoli S, A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31(5):643-6
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Asberg M, Montgomery S, Perris C, A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978;S271:24-8
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338). U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; Rockville, MD: 1976
   Google Scholar